PGNY Share Price Performance
US$26.71
12.10 (82.82%)
9.1% undervalued intrinsic discount
US$29.40
Fair Value
Price US$26.71
AnalystConsensusTarget US$29.40
AnalystLowTarget US$21.00
AnalystHighTarget US$30.25
Fair ValueUS$29.40
Share Pricen/a
Progyny, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 47 Fair Values set on narratives written by author
PGNY Community Narratives
AN
Fair Value US$29.4 9.1% undervalued intrinsic discount
Rising Demand For Women's Health Will Transform Market Opportunity
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
Fair Value US$21 27.2% overvalued intrinsic discount
Tightening US Healthcare Policies And Gig Shifts Will Dampen Prospects
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$32 16.5% undervalued intrinsic discount
Delayed Parenthood And Healthcare Consumerism Will Boost Fertility Ecosystem
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Rising Demand For Women's Health Will Transform Market Opportunity
Key Takeaways Expanding employer focus on women's health and demographic shifts drive robust, recurring demand and client growth for Progyny's fertility benefits and services. Integrated health platform investments and successful upselling boost revenue diversity, client retention, and margin growth while reducing risk from industry concentration.Read more
0users have liked this narrative
0users have commented on this narrative
24users have followed this narrative
AN
US$29.4
9.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
9.11% p.a.
Profit Margin
7.58%
Future PE
25.35x
Price in 2028
US$35.71
Delayed Parenthood And Healthcare Consumerism Will Boost Fertility Ecosystem
Key Takeaways Expanding partnerships and platform innovations are driving stronger insurer adoption, enhancing utilization and pricing power, and positioning the company as essential for employer-offered fertility benefits. Strategic alliances, robust cash flow, and rising demand from younger employees enable brand leadership, accelerating organic growth and offering high optionality for future expansion.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$32
16.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
12.84% p.a.
Profit Margin
8.48%
Future PE
22.65x
Price in 2028
US$38.73
Tightening US Healthcare Policies And Gig Shifts Will Dampen Prospects
Key Takeaways Policy shifts and workforce trends threaten to shrink Progyny's eligible customer base and dampen long-term growth prospects. Intensifying competition, regulatory scrutiny, and disruptive technologies pose risks to profitability, client retention, and future demand for services.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$21
27.2% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
6.25% p.a.
Profit Margin
5.92%
Future PE
21.45x
Price in 2028
US$25.47
Trending Discussion
Recently Updated Narratives
AN
PGNY Emerging IVF Coverage Tailwinds Will Drive Upside Potential
Fair Value: US$29.4 9.1% undervalued intrinsic discount
24 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Tightening US Healthcare Policies And Gig Shifts Will Dampen Prospects
Fair Value: US$21 27.2% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Delayed Parenthood And Healthcare Consumerism Will Boost Fertility Ecosystem
Fair Value: US$32 16.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Progyny, Inc. Key Details
About PGNY
- Founded
- 2008
- Employees
- 678
- CEO
- WebsiteView website
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
